The Latest Cardiac and Vascular News
BAUDETTE, Minn.–(BUSINESS WIRE)–ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prazosin HCl Capsules USP, 1mg and 2mg, following the U.S. Food and Drug Administration’s (“FDA”) approval of the Company’s prior approval supplement application (“PAS”). The current annual U.S. market for Prazosin 1mg and 2mg […]
BAUDETTE, Minn., June 30, 2020 /PRNewswire/ — ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq:ANIP) today announced the launch of Mexiletine Hydrochloride Capsules USP, 150mg, 200mg and 250mg. The current annual U.S. market for this product is approximately $16 million, according to IQVIA/IMS Health. Patrick Walsh, ANI’s Interim President and CEO, stated, “This is our sixth generic […]
BAUDETTE, Minn., Dec. 18, 2019 /PRNewswire/ — ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced the launch of Bretylium Tosylate Injection USP, 50 mg/mL. Bretylium Tosylate is a class III antiarrhythmic medication approved for the treatment of ventricular fibrillation and life-threatening ventricular arrhythmias such as ventricular tachycardia. ANI estimates that the current annual U.S. […]
